Fibrobiologics' cell therapy CYMS101 significantly increased myelin production and promoted myelin repair in a mouse model of MS ...

Find out what happens to heart cells in space and how their adaptation could revolutionize heart disease treatment.

Mesoblast develops allogeneic products based on its proprietary remestemcel-L and rexlemestrocel-L mesenchymal lineage stromal and precursor cell platform technologies. Its allogeneic cellular ...

This fundraise comes following a private investment in public equity (PIPE) investment that the company closed in 2024, ...

Scientists created a stem cell-based method to produce high-quality mitochondria at scale, enabling effective treatments for ...

The board of directors of Grayson-Jockey Club Research Foundation announced that it has authorized expenditure of $2,693,312 to fund 16 new projects and 10 continuing projects at 17 universities as ...

Terumo Blood and Cell Technologies has entered into a memorandum of understanding (MOU) with South Korea’s KBIOHealth to ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid ...

The following is a summary of “A Novel Molecular Regulatory Network in Bone Marrow Mesenchymal Stem Cells for Age-Related Osteoporosis,” published in the March 2025 issue of Clinical Endocrinology by ...

HotCopper favourite Mesoblast (ASX:MSB) has begun treating the first three children with skin graft-versus-host disease in ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Aged individuals and astronauts experience bone loss despite rigorous physical activity. Bone mechanoresponse is in-part ...